Tech
New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Read the full discussion on Wired
This article was aggregated from Wired. Click to join the conversation.
View on Wired
Related Trends in Tech
Can You Build an Agent Entirely in SQL? Almost
Your Client Is Borrowing From You: The Cash Exposure Math of a Freelance Project
Betting on Movement: Options, Futures, and the Art of Risk
Before You Blame the Model, Check the Stack
Tic Tac Toe in SwiftUI, Done Properly: Value-Type State, Win Detection and Minimax AI
Immutable Architecture: Why the Future of AI Models Demands Permanent Storage